About half of melanomas that start in the eye spread to other parts of the body, usually killing people within a year. But while there are a variety of therapies for melanomas in the skin, those in the eyes are biologically distinct and there has been no good way to treat them—until now. A clinical trial of 157 people showed that a drug called selumetinib can shrink melanomas of the eye, which form in a layer called uvea that includes the iris. Selumetinib is a MEK inhibitor that targets the most common uveal mutations (GNAQ and GNA11). The researchers found that tumors shrank in in half of those treated with selumetinib and did not grow again for twice as long compared to those treated with standard chemotherapy (an average of 16 vs 7 weeks). This work was presented at the American Society of Clinical Oncology's 2013 meeting.